Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals

Clin Microbiol Infect. 2018 Jun;24(6):658.e1-658.e6. doi: 10.1016/j.cmi.2017.09.014. Epub 2017 Sep 29.

Abstract

Objectives: Studies on treatment of community-acquired pneumonia (CAP) in China are scarce. We performed a study to investigate empiric antibiotic practices for patients hospitalized with CAP in China and the risk factors for treatment failure.

Methods: Data were collected from a national Chinese hospitalization database. Adult patients who were diagnosed with CAP between 1 October 2014 and 30 September 2015 were identified. We studied initial empiric antibiotic regimens, microbiologic sampling, treatment failure, in-hospital mortality and length of hospital stay.

Results: We included 18 043 adult patients from 185 hospitals who met all the study inclusion criteria. The most common initial antibiotic regimen for CAP was monotherapy with a fluoroquinolone (14.8%, 2671/18 043). The most common initial antibiotic (used alone or in combination with other antibiotics) was levofloxacin (15.7%, 4597/29 278 (this denominator represents the total number of initial antibiotics)). The microbiologic sampling rate was 26.9% (4851/18 043). A total of 4050 (22.4%) of 18 043 patients experienced treatment failure. Multivariate logistic regression demonstrated that older age, male sex, coexisting lung cancer and use of regimens not covering atypical pathogens were risk factors for treatment failure. In-hospital mortality was 2.1% (380/18 043). The median hospital length of stay was 11 days (interquartile range, 8-15 days).

Conclusions: Patients receiving Chinese guideline-adherent regimens had better outcomes, and atypical pathogen active regimens were associated with a lower treatment failure rate and shorter length of hospital stay.

Keywords: Antibiotic therapy; Atypical pathogen covering; Community-acquired pneumonia; Length of stay; Treatment failure.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • China
  • Community-Acquired Infections
  • Female
  • Fluoroquinolones / therapeutic use*
  • Hospital Mortality
  • Hospitalization
  • Humans
  • Length of Stay
  • Levofloxacin / therapeutic use*
  • Logistic Models
  • Male
  • Middle Aged
  • Pneumonia / drug therapy*
  • Pneumonia / mortality
  • Sex Factors
  • Treatment Failure
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Levofloxacin